ABC | Volume 112, Nº5, Maio 2019

Artigo Original Gonzaga et al Modulação autonômica cardíaca em câncer de mama Arq Bras Cardiol. 2019; 112(5):555-563 1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90. 2. WorldHealthOrganization.Breastcancer:preventionandcontrol [Internet]. Geneva: World Health Organization; 2018 [citado nov. 2018]. Disponível em: http://www.who.int/cancer/detection/breastcancer/en/ 3. Vance V, Mourtzakis M, McCargar L, Hanning R. Weight gain in breast cancer survivors : prevalence , pattern and health consequences. Obes Rev. 2011;12(4):282-94. 4. GaoQ, Patani N, Dunbier AK, Ghazoui Z, Zvelebil M, Martin LA, et al. Effect of aromatase inhibition on functional gene modules in estrogen receptor- positive breast cancer and their relationshipwith antiproliferative response. Clin Cancer Res. 2014;20(9):2485-94. 5. Mao H, Bao T, Shen X, Li Q, Seluzicki C, Im EO, et al. Prevalence and risk factors for fatigue among breast cancer survivors on aromatase inhibitors. Eur J Cancer. 2018 Sep;101:47-54. 6. MendelsohnME. Protective effects of estrogen on the cardiovascular system. Am J Cardiol. 2002;89(12A):12E-17. 7. AbderrahmanB, JordanVC.SuccessfulTargetedTherapies forBreastCancer: the Worcester Foundation and Future Opportunities in Women’s Health. Endocrinology. 2018;159(8):2980-90. 8. Caro-MoránE,Fernàndez-LaoC,Galiano-CastilloN,Cantarero-Villanueva I, Arroyo-MoralesM, Dìaz-Rodríguez L. Heart Rate Variability in Breast Cancer Survivors After the First Year of Treatments : A Case-Controlled Study. Biol Res Nurs. 2016;18(1):43-9. 9. Lakoski SG, Jones LW, Krone RJ, Stein PK, Scott JM. Autonomic dysfunction in early breast cancer: incidence, clinical importance, and underlying mechanisms. AmHeart J. 2015;170(2):231-41. 10. Nathan L, ShiW, DinhH, Mukherjee TK,Wang X, Lusis AJ, et al. Testosterone inhibits early atherogenesis by conversion to estradiol: Critical role of aromatase. PNAS. 2001;98(6):3589-93. 11. Mouridsen H, Keshaviah A, Coates AS, Rabaglio M, Castiglione-Gertsch M, Sun Z, et al. Cardiovascular Adverse Events During Adjuvant Endocrine Therapy forEarlyBreastCancerUsingLetrozoleorTamoxifen :safetyanalysis of BIG 1-98 trial. J Clin Oncol. 2007;25(36):5715-22. 12. Allin KH, Nordestgaard BG, Flyger H, Bojesen SE. Elevated pre-treatment levels of plasma C-reactive protein are associated with poor prognosis after breast cancer : a cohort study. Breast Cancer Res. 2011;13(3):R55. 13. Pierce BL, Ballard-Barbash R, Bernstein L, Baumgartner RN, Neuhouser ML, Wener MH, et al. Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. J Clin Oncol. 2009;27(21):3437-44. 14. American Cancer Society. Understanding a Breast Cancer Diagnosis Types of Breast Cancer [Internet]. Atlanta: American Cancer Society; 2018 [citado nov. 2018]. https://www.cancer.org/content/dam/CRC/PDF/ Public/8580.00.pdf. 15. Barbosa MP, Silva NT, Azevedo FM, Pastre CM, Vanderlei LC. Comparison of Polar® RS800G3™ heart rate monitor with Polar® S810i™ and electrocardiogram to obtain the series of RR intervals and analysis of heart rate variability at rest. Clin Physiol Funct Imaging. 2016;36(2):112-7. 16. Tarvainen MP, Niskanen JP, Lipponen JA, Ranta-Aho PO, Karjalainen PA. Kubios HRV -- heart rate variability analysis software. Comput Methods Programs Biomed. 2014;113(1):210-20. 17. Task Force of The European Society of Cardiology and The North American Society of Pacing and Electrophysiology. Heart rate variability: standards of measurement, physiological interpretation, and clinical use. Eur Heart J. 1996;17(3):354-81. 18. Vanderlei LC, Pastre CM, Hoshi RA, Carvalho TD, Godoy MF. Basic notions of heart rate variability and its clinical applicability. Rev Bras Cir Cardiovasc. 2009;24(2):205-17. 19. Neves VFC, Perpetuo NM, Sakabe DI, Catai AM, Gallo Jr L, Silva de Sá MF, et al. Analysis of spectral indexes for heart rate variability in middle-aged men and postmenopausal women. Rev Bras Fisioter. 2006;10(4):401-6. 20. Friedenreich CM, Neilson HK, Woolcott CG, Wang Q, Stanczyk FZ, Mctiernan A, et al. Inflammatory marker changes in a yearlong randomized exercise intervention trial among postmenopausal women. Cancer Prev Res. 2012;5(1):98-108. 21. Giese-Davis J, Wilhelm FH, Tamagawa R, Palesh O, Neri E, Taylor CB, et al. Higher vagal activity as related to survival in patients with advanced breast cancer: an analysis of autonomic dysregulation. Psychosom Med. 2017;77(4):346-55. 22. Thayer JF, Lane RD. The role of vagal function in the risk for cardiovascular disease and mortality. Biol Psychol. 2007;74(2):224-42. 23. Saarto T, Sievanen H, P Kellokumpu-Lehtinen P, Nikander R, Vehmanen L, Huovinen R, et al. Effect of supervised and home exercise training on bone mineral density among breast cancer patients. A 12-month randomised controlled trial. 2012;23(5)1601-12. 24. ErinN, Akdas BG, Harms JF, ClawsonGA. Vagotomy enhances experimental metastases of 4THMpc breast cancer cells and alters substance P level. Regul Pept. 2008;151(1-3):35-42. 25. Greenland P, Alpert JS, Beller GA, Benjamin EJ, Budoff MJ, Fayad ZA, et al. 2010 ACCF / AHA Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults: a report of the American College of Cardiology Foundation/ AmericanHeart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2018;56(25):e50-103. 26. Rinaldi W, Ribeiro TAS, Marques AS, Fabricio GS, Tofolo LP, Gomes RM, et al. Effect of small litter size on the autonomic and metabolic responses of Wistars rats. Rev. Nutr. 2012;25(3):321-30. Referências Este é um artigo de acesso aberto distribuído sob os termos da licença de atribuição pelo Creative Commons 563